Objective To observe the curative effect of Tongmai Yangxin Wan on atrial arrhythmias of coronary heart disease (CHD). Methods The patients (n=120) were chosen from Department of Cardiology of the First Central Hospital of Baoding City in Hebei Province from Jan. 2015 to Jan. 2018, and then divided randomly into study group and control group (each n=60). The control group was given routine treatment and study group was additionally given Tongmai Yangxin Wan for 4 weeks as a course of treatment. The clinical efficacy, times and duration of arrhythmias attack and 6-minute walk distance (6MWD) were compared, and adverse reactions were recorded in 2 groups. Results After treatment, the total effective rate was 80.0% in study group, which was significantly higher than that in control group (56.7%). The times and duration of arrhythmias attack and 6MWD were superior in study group to those in control group (P＜0.05). There were no adverse reactions observed in 2 groups. Conclusion Tongmai Yangxin Wan can effectively relieve the clinical symptoms and improve exercise tolerance in patients with atrial arrhythmias of CHD, and it is worthy of clinic application.%目的 观察通脉养心丸治疗冠状动脉粥样硬化性心脏病(冠心病)房性心律失常中的疗效.方法 收集2015年1月至2018年1月期间于保定市第一中心医院心内科住院的120例患者随机分为研究组和对照组各60例.其中,对照组予常规治疗,研究组在此基础上加用通脉养心丸,4周为一疗程.比较临床疗效、心律失常发作次数及持续时间、6 min步行距离(6MWD),记录不良反应.结果 治疗后,研究组总有效率为80.0%,明显高于对照组的56.7%;与对照组相比,研究组心律失常发作次数及持续时间、6MWD均明显较优(P＜0.05).两组均无明显不良反应出现.结论 通脉养心丸能有效改善冠心病房性心律失常患者的临床症状,并能提高运动耐力,值得临床推广应用.
展开▼
